Russia Remains Heavily Dependent on Western Medicines Despite Industrial Sovereignty Ambitions
Despite President Vladimir Putin's strategic priority of achieving economic and industrial independence, Russia remains heavily reliant on medicines manufactured abroad, particularly in Western countries. A Bloomberg survey, based on data from Russian research firm DSM, reveals that 56% of Russia's spending on medicines during the first eight months of this year was on imported products. This figure shows little change from 2022, when imports accounted for 57% of expenditure, indicating that Russia's dependence on foreign medicines has barely diminished in four years. Medicines have been exempted from Western sanctions on humanitarian grounds, allowing pharmaceutical exports from the European Union to Russia to increase even as overall European exports have sharply declined. Major Western pharmaceutical companies like Roche, Novartis, AstraZeneca, and Sanofi continue to be significant players in the Russian market.
